At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jul 27, 2026 at 18:45 ET
CG Oncology published Phase 3 BOND-003 Cohort C results for cretostimogene in BCG-unresponsive NMIBC in The Lancet Oncology, showing a 75.5% complete response rate, median duration of response of 27.9 months, and no Grade 3+ treatment-related adverse events. The publication validates the clinical data ahead of a potential FDA decision, reinforcing the drug's profile as a potential bladder-sparing therapy in a high-need setting with no approved standard of care alternatives beyond cystectomy.
- Phase 3 BOND-003 Cohort C met its primary endpoint with statistical significance; 75.5% of patients achieved complete response at any time.
- Median duration of response was at least 27.9 months and is ongoing; 64.2% and 60.1% maintained response at 12 and 24 months, respectively.
- No Grade 3 or greater treatment-related adverse events, treatment-related discontinuations, or deaths reported.
- 96.6% of patients were free from progression to muscle-invasive bladder cancer at 48 and 96 weeks.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access